To ask the Secretary of State for Health, with reference to the draft Joint Committee on Vaccination and Immunisation minutes of 2 October 2013, which organisation or individual advised the Joint Committee to conduct an independent review of the health economic components of the cost-effectiveness evaluation of Bexsero; and on what grounds such advice was provided.

The Joint Committee on Vaccination and Immunisation (JCVI) was advised to conduct an independent review of the health economic components of the cost-effectiveness evaluation of Bexsero by the meningococcal sub-committee of the JCVI following their meeting of 20 September 2013.

On 24 July 2013, JCVI published an interim statement on the use of Bexsero® in the United Kingdom. A period of consultation followed and comments were invited and received from key stakeholders. Having considered information in the stakeholder submissions, the meningococcal sub-committee advised JCVI that a review of the cost-effectiveness evaluation of Bexsero® was appropriate.